Expert Opinion on Emerging Drugs

eISSN: 1744-7623pISSN: 1472-8214

Journal formatting to fit the target journal guidelines

Experts ensure all elements of your paper match journal formatting guidelines to improve publication success rate!

Aims and Scope

Expert Opinion on Emerging Drugs is a quarterly peer-reviewed medical journal publishing structured reviews on drugs/drug classes emerging onto the market across all therapy areas. Each review includes an "expert opinion" section, in which authors are asked to provide their personal view on the current status and future direction of the research discussed. It was established as Emerging Drugs in 1996, changing to its current name in 2001. It is published by Informa. According to the Journal Citation Reports, the journal has a 2014 impact factor of 3.058. Less

Key Metrics

CiteScore
5.6
Eigenfactor
0.001 - 0.005
H-Index
52
Impact Factor
< 5
SJR
Q1Pharmacology
SNIP
0.8
3
Time to Publish
time-to-publish View Chart
3  Mo

Journal Specifications

Overview
  • Publisher
    TAYLOR & FRANCIS LTD
  • Language
    English
  • Frequency
    Quarterly
General Details
View less

Ready to spotlight your research findings?

Impress peers and journals alike with a concise, visual summary of your work.

Meets Top Publisher Standards: Essential for leading journals like Elsevier.
Enhances Engagement: Research papers with graphical abstracts receive 3X more downloads and 8X more shares.
Tailored Just for You: We’ll create a custom graphical abstract based on your manuscript—no sketches needed.
Learn more 3000+ graphical abstracts produced with 4.8/5 customer rating
Time to Publish
Time to publish distribution
Articles published in year 2022
Time to publish index
Months% Papers published
0-3 43%
4-6 54%
7-9 3%
>9 0%

Topics Covered

Immune checkpoint inhibitors
Epidermolysis bullosa
Tumor microenvironment
Major depressive disorder
Synthetic drugs
Cirrhosis
Chronic myelomonocytic leukemia
Adrenocortical carcinoma
Cytotoxic chemotherapy
Standard of care
Antibody therapy
Nonalcoholic fatty liver disease
Imatinib
Sunitinib
Treatment options
Regorafenib
Immunotherapy

Year-wise Publication

FAQs

Since when has Expert Opinion on Emerging Drugs been publishing? Faqs

The Expert Opinion on Emerging Drugs has been publishing since 2001 till date.

How frequently is the Expert Opinion on Emerging Drugs published? Faqs

Expert Opinion on Emerging Drugs is published Quarterly.

What is the H-index. SNIP score, Citescore and SJR of Expert Opinion on Emerging Drugs? Faqs

Expert Opinion on Emerging Drugs has a H-index score of 52, Citescore of 5.6, SNIP score of 0.8, & SJR of Q1

Who is the publisher of Expert Opinion on Emerging Drugs? Faqs

The publisher of Expert Opinion on Emerging Drugs is TAYLOR & FRANCIS LTD.

Where can I find a journal's aims and scope of Expert Opinion on Emerging Drugs? Faqs

For the Expert Opinion on Emerging Drugs's Aims and Scope, please refer to the section above on the page.

How can I view the journal metrics of Expert Opinion on Emerging Drugs on editage? Faqs

For the Expert Opinion on Emerging Drugs metrics, please refer to the section above on the page.

What is the eISSN and pISSN number of Expert Opinion on Emerging Drugs? Faqs

The eISSN number is 1744-7623 and pISSN number is 1472-8214 for Expert Opinion on Emerging Drugs.

What is the focus of this journal? Faqs

The journal covers a wide range of topics inlcuding Immune checkpoint inhibitors, Epidermolysis bullosa, Tumor microenvironment, Major depressive disorder, Synthetic drugs, Cirrhosis, Chronic myelomonocytic leukemia, Adrenocortical carcinoma, Cytotoxic chemotherapy, Standard of care, Antibody therapy, Nonalcoholic fatty liver disease, Imatinib, Sunitinib, Treatment options, Regorafenib, Immunotherapy.

Why is it important to find the right journal for my research? Faqs

Choosing the right journal ensures that your research reaches the most relevant audience, thereby maximizing its scholarly impact and contribution to the field.

Can the choice of journal affect my academic career? Faqs

Absolutely. Publishing in reputable journals can enhance your academic profile, making you more competitive for grants, tenure, and other professional opportunities.

Is it advisable to target high-impact journals only? Faqs

While high-impact journals offer greater visibility, they are often highly competitive. It's essential to balance the journal's impact factor with the likelihood of your work being accepted.